The United States Food and Drug Administration (USFDA) has concluded the General GMP inspection at Piramal Pharma’s Turbhe facility. The inspection conducted from February 11, 2025 to February 17, 2025.
On conclusion of the inspection, a Form-483 was issued with 6 observations. Observations are largely around improvement of procedures and practices and not related to data integrity. The Company is preparing a detailed response to said observations, which will be submitted to agency within stipulated timelines. The Company remains committed to maintain a highest standards of compliance and is confident of effective closure of observations.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1647.95 |
| Dr. Reddys Lab | 1215.90 |
| Cipla | 1213.25 |
| Zydus Lifesciences | 911.00 |
| Lupin | 2320.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: